![]() Hansen, during the conference call, alluded to the fact that the company has received substantial interest from pharma majors in the T-cell pre-partnered assets along with interest from partners wishing to utilize AbCellera's engine to develop their own candidates. You may be asking, ok, that's great, but show me the money?!?! Be patient my inquisitive friend, I believe it is only a matter of time until the company delivers the goods.ĭr. The fact that the company has been able to develop and catalog these antibodies, a feat that AbCellera claims, surpasses all others in the industry, during a period of only 18 months, is astounding. As such, we believe this is a technological advance that has broad implications for precision oncology. Importantly, TCR mimetic antibodies can also be used in other therapeutic modalities, including antibody drug conjugates, radio, pharmaceuticals and cell therapy. This result shows that we have capabilities that can readily address a large and essentially untouched class of tumor targets for TCEs. Perhaps most significant is the speed and ease with which this result was obtained from a single screening campaign and without the need for subsequent antibody engineering. We screened more than a million cells and found more than a dozen fully human antibodies with high affinity, good development ability and specificity to MAGE-A4 that is comparable or superior to the clinical benchmark. Because there are many more cancer specific proteins expressed inside cancer cells, the ability to target these with antibodies would open up a huge number of potential targets. Central to this challenge is that there are few known proteins that are expressed only on the surface of cancer cells and not on the surface of healthy cells. In our second poster, we presented an approach to addressing the second challenge of finding antibodies that are highly specific to cancer cells. This panel offers unmatched diversity of binding properties and binding locations, excellent developability and is highly differentiated from commonly used molecules. First, we have built what we believe to be by far the industry's largest collection of CD3 binders with more than 500 unique antibodies. Key results from this poster as are as follows. One of our posters that at ACR demonstrated data on our newly generated CD3 panel and its use in building optimized TCEs against to cancer targets EGFR and PSMA. Carl Hansen explained the following on the conference call in his prepared remarks: This catalog of antibodies, AbCellera claims, is by far the largest in the world of its kind and the breadth, speed and diversity of the panel may in fact be groundbreaking in the treatment of cancer.ĬEO Dr. These data show that the company, using its platform and with relative ease I may add, has been able to gather, catalog and analyze over 500 unique and potent bi-specific antibodies that appear to be comparable, or superior to clinical benchmarks. Under the surface however, the company continues to deliver on exactly what management has been telegraphing for some time now, fireworks to come from the pre-partnered programs effort, specifically, the T-cell engager programs.ĭuring the quarter, the company presented a trove of data highlighting the progress of the T-cell engager technology development effort it is currently pursuing. Not a stellar quarter for headlines in newsfeeds. The company only signed one new partnership, adding 3 new programs during the quarter, while the company reported that AbCellera partner, Teva Pharmaceutical ( TEVA), advanced a neurology molecule, discovered by AbCellera, into the clinic during the quarter, the company also reported no new program starts and the cash balance shrunk by over $90 million to $824 million. The first quarter, on the surface, appeared to be a rather boring and unproductive affair. In this article, I would like to dive into the quarter, specifically, the conference call around the TCE programs and explain my continued bullishness for the future. In the first quarter, AbCellera continued to deliver positive business momentum, only to be rewarded with further deep, on paper, shareholder losses. Investing has a sadistic way of making you feel like you are the man in the above photo, with a massive pot of gold hiding somewhere in a vast labyrinth of wrong turns and dead ends.īeing a shareholder of AbCellera Biologics ( NASDAQ: ABCL ) over the last few years, I would argue, has been equally as frustrating however, I would also argue that the last few years have been nothing short of a tremendous success for the company itself from an "under the hood" business perspective.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |